Genetic Risk Factors for Inhibitor Development in Patients with Hemophilia and Rare Bleeding Disorders
Journal of Cellular & Molecular Anesthesia,
Vol. 2 No. 1 (2017),
1 Dey 2017
,
Page 19-23
https://doi.org/10.22037/jcma.v2i1.14481
Abstract
Inhibitor development is a lifelong challenge for patients with bleeding disorders who received replacement therapy. Most commonly, inhibitor formation was observed in hemophilia A patients but patients with rare bleeding disorders (RBD) especially patients with deficiency of factor XIII (FXIII) and factor V (FV) can develop an inhibitor against exogenous factors. Several factors considered as risk factors for inhibitor formations in these patients. Genetic risk factors are the main accused that can cause inhibitor formation in hemophilia patients but are less important in RBDs.
For this review study, we searched MEDLINE and Web of Science databases for English sources and the following key words: hemophilia, inhibitor, rare bleeding disorder, rare inherited disorder, acquired hemophilia, acquired rare bleeding disorders, treatment complication, genetic in hemophilia, polymorphism in rare bleeding disorder, mutation in hemophilia and other required keywords.
Hemophilia A (HA) patients who had large deletion, nonsense mutation or intron 22 inversion are more susceptible for inhibitor development. Gene polymorphisms in immune system are also considered as other risk factors in HA patients.
Keywords: Hemophilia, rare bleeding disorder, inhibitor
- Hemophilia
- rare bleeding disorder
- inhibitor
How to Cite
References
Dorgalaleh A, Dadashizadeh Gh, Bamedi T. Hemophilia in Iran. Hematology. 2016;21(5):300-10.
Dorgalaleh A, Tabibian Sh, Diagnosis, Clinical manifestations and Management of Rare Bleeding Disorders in Iran, Hematology, 2016.
Key NS. Inhibitors in congenital coagulation disorders. British journal of haematology. 2004;127(4):379-91.
Cohen AJ, Kessler CM. 9 Acquired inhibitors. Baillière's clinical haematology. 1996;9(2):331-54.
Franchini M, Lippi G. Acquired factor VIII inhibitors. Blood. 2008;112(2):250-5.
Saint‐Remy JM, Lacroix‐Desmazes S, Oldenburg J. Inhibitors in haemophilia: pathophysiology. Haemophilia. 2004;10(s4):146-51.
Oldenburg J, Pavlova A. Genetic risk factors for inhibitors to factors VIII and IX. Haemophilia. 2006;12(s6):15-22.
Oldenburg J, Schröder J, Brackmann HH, Müller-Reible C, Schwaab R, Tuddenham E, editors. Environmental and genetic factors influencing inhibitor development. Seminars in hematology; 2004: Elsevier.
Gouw SC, van den Berg HM. The multifactorial etiology of inhibitor development in hemophilia: genetics and environment. Semin Thromb Hemost. 2009;35(8):723-34.
Nesheim ME, Nichols WL, Cole TL, Houston JG, Schenk RB, Mann KG, et al. Isolation and study of an acquired inhibitor of human coagulation factor V. Journal of Clinical Investigation. 1986;77(2):405.
SUETSUGU Y, MIKAMI M, OTSUKI T, YAWATA Y, SUGIHARA T. Acquired Factor V Inhibitor.
Franchini M, Lippi G. Acquired factor V inhibitors: a systematic review. Journal of thrombosis and thrombolysis. 2011;31(4):449-57.
Ang AL, Kuperan P, Ng CH, Ng HJ. Acquired factor V inhibitor-A problem-based systematic review. Thromb Haemost. 2009;101(5):852-9.
Salomon O, Zivelin A, Livnat T, Dardik R, Loewenthal R, Avishai O, et al. Prevalence, causes, and characterization of factor XI inhibitors in patients with inherited factor XI deficiency. Blood. 2003;101(12):4783-8.
Duga S, Salomon O. Factor XI deficiency. Semin Thromb Hemost. 2009 Jun;35(4):416-25.
Dorgalaleh, A. and J. Rashidpanah. Blood coagulation factor XIII and factor XIII deficiency. Blood Rev. 2016; 30(6):461-75.
Dorgalaleh, A., S. Tabibian, et al. Guidelines for laboratory diagnosis of factor XIII deficiency. Blood Coagul Fibrinolysis. 2016;27(4):361-4
Dorgalaleh A, Naderi M. Morbidity and mortality in a large number of Iranian patients with severe congenital factor XIII deficiency. Ann Hematol. 2016;95(3):451-5.
- Abstract Viewed: 752 times
- PDF Downloaded: 393 times